Subscribe to the gold package and get unlimited access to Shamra Academy
Register a new userمقارنة نجاعة ومأمونية نظم الأنسولين المستخدمة في تدبير فرط سكر الدم لدى مرضى السكري من النمط الثاني في المستشفيات
548
0 0
0.0
(
0
)
Added by
Damascus University رسالة ماجستير
Publication date
2015
fields
Pharmacy
and research's language is
العربية
Created by
Shamra Editor
Ask ChatGPT about the research
مقارنة نجاعة ومأمونية نظم الأنسولين المستخدمة في تدبير فرط سكر الدم لدى مرضى السكري من النمط الثاني في المستشفيات
No English abstract
References used
American Diabetes Association costs of diabetes in the U.S. in 2007 Diabetes Care 2008
rate research
Read More
Type 2 Diabetes mellitus T2DM has been suggested to be the most common
metabolic disorder associated with magnesium deficiency which has many adverse
outcomes. The aim of this study was to evaluate plasma Mg in 126 T2DM patients
recruited from Dia
betes Centre in Lattakia, compare them to 70 healthy individuals, and
assess the correlation between plasma Mg and HbA1c as a glycemic control biomarker.
Magnesium was measured using xylidyl blue colorimetric method. HbA1c was measured
using ion-exchange resin separation. The SPSS 19.0 software was used for statistical
analysis. Mean plasma Mg concentrations of the diabetics was significantly lower than
controls (P=0.0001). Plasma magnesium was negatively correlated with HbA1c (r=-0.5,
P=0.0002). Plasma magnesium was below the normal reference range (1.9-2.5 mg/dL) in
47.6% of diabetics and 28.6% of controls. In conclusion, it is important to monitor Mg
levels in both T2DM patients and non-diabetics and take procedures to correct
hypomagnesaemia states.
The purpose of the research is to identify the level of the
meaning of life and the psychological Hardiness of the research
sample and identify the correlation between the meaning of life and
psychological Hardiness, and to know the differences between the
average scores of the patients of the research sample on the scale of
life meaning and psychological Hardiness according to the variable
years of infection.
Background: Diabetes mellitus type2 (T2DM) and thyroid dysfunction (TD) are the
two most common endocrine disorders in clinical practice. The unrecognized TD may
adversely affect the metabolic control and add more risk to an already predisposing
s
cenario for cardiovascular diseases. The objective of this study was to investigate the
prevalence of TD in patients with type2 diabetes mellitus.
Objective: To determine the prevalence and patterns of thyroid dysfunction in
patients with type2 diabetes mellitus.
Material and methods: Study included total 362 subjects (204 type2 diabetic patients
and 158 healthy non diabetic subjects). Agroup of type2 diabetic patients and control group
were evaluated for thyroid dysfunction by testing TSH and FT4 when TSH was abnormal.
The correlation of prevalence of thyroid disorder with gender distribution, age distribution,
duration of diabetes, BMI, treatment, fasting plasma glucose (FPG), serum triglyceride and
serum cholesterol was then done in diabetic patients. The observations and interpretations
were recorded and results obtained were statistically analyzed.
Results: The prevalence of thyroid dysfunction among type2 diabetic patients was
found to be 13,2%. In the control group, the prevalence of thyroid dysfunction was 6,3%.
There was a significant difference between diabetics and control subjects p= 0,031.The
most frequently TD in type2 diabetic patients was subclinical hypothyroidism (8,3%).
Thyroid dysfunction was significantly correlated with gender (women > man), age < 60
years, FPG > 130mg/dl, TG > 150mg/dl and insulin treatment in type2 diabetic patients.
Conclusion: Screening of thyroid dysfunction shoud be done in all Type2 diabetic
patients.
Many T2D use CAO as a laxative. We did not find sufficient research to explain CAO's potential effect on the levels of HbA1c in T2D patients. This study will study this effect. Rats (n=80) were divided into eight groups (n=10). Five groups (n=50) wer
e injected with streptozotocin intravenously to induce T2D. One group was given CAO with empagliflozin, and the second was assigned CAO only daily. The third was assigned CAO every two days, with empagliflozin, which was given daily. A fourth was assigned CAO alone daily. Also, the fifth was given empagliflozin alone. In the healthy groups, one group was given CAO, and the other was given empagliflozin. Also, the last healthy group was not assigned any drug. CAO's result on HbA1c in healthy rats was noted to decrease when delivered alone for eight weeks. HbA1c of the diabetic groups showed no significant difference (P-value<0.05) when comparing the rats given CAO with empagliflozin, and the rats were given CAO only. There was also no noticeable effect among the groups of rats given CAO daily and every two days. This study explains that CAO does not lead to a significant difference in HbA1c levels in diabetic rats, even it did for healthy rats, and if given alone, CAO could affect HbA1c levels if given over a long period. Also, CAO has a noticeable impact on experimental rats that co-administered Empagliflozin on HbA1c levels, and that Empagliflozin effect is not significantly affected if taken with CAO.
This study aims to compare between two globally approved strategies to manage diabetes type II in Syria, by comparing their effectiveness in patients with diabetes type II who are treated in the national program of diabetes Clinics in Damascus and in
vestigate their glucose control. The first strategy includes glibenclamide as a monotherapy and the second includes a combination of glibenclamide and metformin.
Log in to be able to interact and post comments
comments
Fetching comments
Sign in to be able to follow your search criteria
